Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs

Treatment with immune checkpoint inhibitors (ICIs) has improved the prognosis of melanoma patients. However, ICIs can cause an overactivation of the immune system followed by diverse immunological side effects known as immune-related adverse events (irAE). Currently, the toxicity of irAE is limiting...

全面介紹

書目詳細資料

發表在:	OncoImmunology
Main Authors:	Alisa Lepper, Rebekka Bitsch, Feyza Gül Özbay Kurt, Ihor Arkhypov, Samantha Lasser, Jochen Utikal, Viktor Umansky
格式:	Article
語言:	英语
出版:	Taylor & Francis Group 2023-12-01
主題:	Immune-related adverse events immunotherapy melanoma
在線閱讀:	https://www.tandfonline.com/doi/10.1080/2162402X.2023.2247303